Last reviewed · How we verify
Losartan + Simvastatin
This combination reduces blood pressure via angiotensin II receptor blockade and lowers cholesterol via HMG-CoA reductase inhibition, addressing both hypertension and dyslipidemia simultaneously.
This combination reduces blood pressure via angiotensin II receptor blockade and lowers cholesterol via HMG-CoA reductase inhibition, addressing both hypertension and dyslipidemia simultaneously. Used for Hypertension with concurrent hyperlipidemia, Cardiovascular risk reduction in patients requiring both antihypertensive and lipid-lowering therapy.
At a glance
| Generic name | Losartan + Simvastatin |
|---|---|
| Sponsor | University of Pavia |
| Drug class | Angiotensin II receptor antagonist + HMG-CoA reductase inhibitor (statin) |
| Target | Angiotensin II type 1 receptor (AT1R) + HMG-CoA reductase |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Losartan blocks angiotensin II type 1 receptors, causing vasodilation and reducing blood pressure and aldosterone secretion. Simvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, reducing LDL cholesterol and triglycerides. Together, they provide complementary cardiovascular risk reduction in patients with both hypertension and hyperlipidemia.
Approved indications
- Hypertension with concurrent hyperlipidemia
- Cardiovascular risk reduction in patients requiring both antihypertensive and lipid-lowering therapy
Common side effects
- Dizziness
- Fatigue
- Muscle pain or myalgia
- Elevated liver enzymes
- Hyperkalemia
- Cough
Key clinical trials
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (PHASE3)
- Fixed Dose Intervention Trial of New England Enhancing Survival in SMI Patients (PHASE4)
- Early Rheumatoid Arthritis COR Intervention (NA)
- The Canadian Prevention of Renal and Cardiovascular Endpoints Trial (NA)
- Study to Evaluate the Effect of Simvastatin, Losartan and Pioglitazone on Patients With Peripheral Arterial Disease. (EARLY_PHASE1)
- Coronavirus Response - Active Support for Hospitalised Covid-19 Patients (PHASE3)
- Clinical Study to Evaluate Adherence Improvement Fixed-dose Combination of Olostar Tab. in Patients With Hypertension and Dyslipidemia (PHASE4)
- Losartan and Simvastatin in Hypertensive Obeses With Liver Steatosis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Losartan + Simvastatin CI brief — competitive landscape report
- Losartan + Simvastatin updates RSS · CI watch RSS
- University of Pavia portfolio CI